HUTCHISON CHINA/S (NASDAQ:HCM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong. “

Separately, BidaskClub downgraded HUTCHISON CHINA/S from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 16th.

HCM stock opened at $31.31 on Wednesday. The firm has a market capitalization of $4.38 billion, a PE ratio of -142.32 and a beta of 0.01. HUTCHISON CHINA/S has a 1 year low of $25.76 and a 1 year high of $42.25. The company has a current ratio of 4.67, a quick ratio of 4.55 and a debt-to-equity ratio of 0.06.

Large investors have recently bought and sold shares of the business. Royal Bank of Canada bought a new stake in HUTCHISON CHINA/S during the first quarter valued at about $199,000. Renaissance Technologies LLC increased its holdings in shares of HUTCHISON CHINA/S by 375.0% in the third quarter. Renaissance Technologies LLC now owns 32,300 shares of the company’s stock worth $1,040,000 after purchasing an additional 25,500 shares during the last quarter. Millennium Management LLC bought a new stake in shares of HUTCHISON CHINA/S in the first quarter worth about $1,009,000. State of New Jersey Common Pension Fund D bought a new stake in shares of HUTCHISON CHINA/S in the second quarter worth about $2,651,000. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its position in HUTCHISON CHINA/S by 12.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 121,430 shares of the company’s stock worth $3,660,000 after acquiring an additional 13,345 shares in the last quarter. 11.79% of the stock is currently owned by institutional investors and hedge funds.

HUTCHISON CHINA/S Company Profile

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.

See Also: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on HUTCHISON CHINA/S (HCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.